Gate News message, April 15 — Amazon Web Services (AWS) has launched Amazon Bio Discovery, an AI application designed for early-stage drug discovery. The platform enables scientists to run computational workflows without coding and send shortlisted molecules to lab partners for synthesis and testing.
The product combines biological foundation models that generate and evaluate drug molecules with an AI agent that assists users in selecting models, setting parameters, and interpreting results. Early adopters include Bayer, the Broad Institute, and Voyager Therapeutics. AWS Vice President for Healthcare AI and Life Sciences Rajiv Chopra stated that work previously requiring 18 months to produce 300 potential drug candidates can now be completed in a couple of weeks.
The service will begin with a free trial offering five experimental units before transitioning to subscription-based pricing tiers.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.
Related Articles
OpenAI Executives Bill Peebles and Kevin Weil Depart in Leadership Reshuffle
OpenAI executives Bill Peebles and Kevin Weil announced their exits, part of a series of leadership changes as the company decentralizes its operations. Their departures follow several other high-profile exits and a shift in company structure.
GateNews48m ago
Zoom Partners with World to Add Deepfake Detection Using Facial Recognition
Zoom has partnered with Sam Altman's World to launch a feature detecting real participants versus AI deepfakes during video calls. This aims to combat increasing deepfake fraud, with verification options for hosts and participants.
GateNews58m ago
AI-Generated Bug Reports Overwhelm cURL Maintenance Team
AI-generated bug reports are overwhelming the cURL project, with a significant rise in submissions leading to resource strain. Maintainers are responding by limiting AI model access and pausing vulnerability reward programs to manage the influx.
GateNews1h ago
xAI Launches Grok Speech-to-Text and Text-to-Speech APIs
xAI launched speech-to-text and text-to-speech APIs for its Grok platform, enabling developers to integrate natural voice interactions into applications. This update enhances user experience and accessibility for various use cases.
GateNews1h ago
Cursor Raises $2B at $50B Valuation Led by Thrive Capital
Cursor, an AI coding startup, is set to raise at least $2 billion at a $50 billion valuation, led by Thrive Capital and Andreessen Horowitz. It aims for over $6 billion in revenue by 2026 and distinguishes itself with a tiered pricing model and SOC 2 Type 2 certification.
CryptoFrontier1h ago
Iconiq Wealth Manager Prepares to Raise Billions for New AI Fund
Iconiq, a San Francisco-based wealth manager, plans to raise a new fund focused on AI investments, having previously invested over $3 billion in AI startups in 2025. The firm's investor base has shifted to include more institutional backers, and it recently made six new AI investments.
GateNews2h ago
